Research programme: pain therapeutics - ImmuPharma
Alternative Names: IPP-102199Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator ImmuPharma
- Class Opioid peptides
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer pain; Pain; Postoperative pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer-pain in France (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in France (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Postoperative-pain in France (PO)